Market Report Source

Overview

With increased pricing pressure from generics, limited differentiation among new medicines and pipeline products and declining sales growth, the women’s health market is facing threatening competitive forces, prompting major pharmaceutical players to initiate key strategic changes. The Women’s Health Market Outlook to 2011 is a new report providing analysis of the current and future market for women’s health drugs across all major indications. Forecasts are given based on current marketed portfolio, drivers and resistors of growth and R&D pipelines, enabling you to predict changes in the dynamics of the global women’s health market. Key indications covered in this report are osteoporosis, infertility, uterine fibroids, endometriosis, urinary incontinence and gynecological infections.

Key findings of this new report:

• The leading hormonal contraceptive brand in 2005 was Schering AG’s (now Bayer Schering Pharma) Yasmin which accrued $666m in sales. Schering has recently launched a low dose version of Yasmin,called Yaz which has been approved in the additional indications of acne and PMDD and is forecast to accrue $730m in sales by 2011
• Of the newly launched products that are considered to be associated with strong potential success, GSK’s Boniva (ibandronate) indicated for the treatment of osteoporosis is forecast to accrue $1,309m by the end of the forecast period in 2011.
• Although Merck held the leading position among competing companies in the WH market in 2005, its marketed franchise comprises of a lone product, Fosamax, with an indication in osteoporosis Fosamax and its reformulated counter part Fosamax PLUS D which accrued combined sales of $2,845m in 2005.

Your questions answered:

• What indications are driving current growth in this therapeutic area?
• What are the current trends within the major indications such as osteoporosis, urinary incontinence and sub indications of HRT?
• How important are drug delivery and reformulation strategies to product innovation and life cycle strategies in this therapeutic area?
• Which indications within this therapeutic market are forecast to benefit the most from new product development activity in the next few years?
• Which indication is forecast to feature the strongest performance in terms of new sales from new launches by major pharmaceutical companies?
• Which companies are best positioned for success in this therapeutic area and why?

This report will enable you to…

• Quantify patient potential, assess treatment trends and sales patterns with this report’s in-depth coverage of the major women’s health indications.
• Forecast sales of the major products in the women’s health area over the period 2006-11 in major indications, classes of treatments and by company.
• Evaluate how market share of leading companies, such as Merck, GlaxoSmithKline and Pfizer, will change over the next 6 years, and assess your competitive position within the market.
• Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of major classes of women’s health treatments.

Table of Contents

Women’s Health Market Outlook to

Executive Summary

Patient potential

Global market analysis

Competitive landscape

Chapter 1 Epidemiology of Women’s Health

Summary

Introduction

Osteoporosis

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Hormonal Contraception

Overview

Prescription and management

Epidemiology

Forecast epidemiology

Urinary Incontinence

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Common gynecological infections

Overview

Candidiasis

Vaginosis

Trichomoniasis

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Hormone replacement therapies

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Chapter 2 Global market analysis

Summary

Introduction

Market analysis by country

Licensing trends

Market analysis by drug class

Leading brands dynamics

Key events in the market

Bayer acquires Schering AG to form Bayer-Schering Pharma

Safety concerns associated with the use of transdermal release system

formulations of hormonal contraceptives

Association of jaw bone necrosis with the long term use of bisphosphonates

in the treatment of osteoporosis

Arrival of generic competition to market-leading anti-infectives treatments

Launch of Plan B emergency contraceptive in the US market

Urinary incontinence market analysis

Market dynamics

Key brands analysis

Urinary incontinence sales forecasts to 2011

Anti-infectives market analysis

Market dynamics

Key brands analysis

Anti-infectives sales forecasts to 2011

Osteoporosis

Leading brands of Osteoporosis market

Competitive dynamics of subclasses of osteoporosis treatments

Bisphosphonates market analysis

Market dynamics

Key brands analysis

Calcitonins

Market dynamics

Key brands analysis

Osteoporosis sales forecasts to 2012

Hormonal contraception

Competitive dynamics of subclasses of hormonal contraceptives

Leading brands of Hormonal Contraceptives

Key brands analysis

Hormonal contraceptives sales forecasts to 2012

Hormone Replacement Therapy

Competitive dynamics of subclasses of the Hormone Replacement Therapy

market

Leading brands of Hormone replacement therapies

Market dynamics

Key brands analysis

Hormonal replacement therapy sales forecasts to 2012

Total Women’s health market sales forecasts to 2011

Chapter 3 Pipeline analysis

Summary

Introduction

Key trends in R&D

New drug delivery formulations

Reformulations

Extended cycle regimes

New dosing regime

Second-generation anticholinergics in urinary incontinence

The women’s health pipeline

Leading drugs in development

Profiles of key pipeline products

Phase II compounds

NBI-56418

Nesterone

Phase III compounds

J867 (asoprisnil)

Org 36286 (corifollitropin alfa )

Drugs in registration

Pristiq (desvenlafaxine)

Viviant (bazedoxifene)

Evamist (estradiol MDTS)

Lybrel/Librel/Anya (levonorgestrel/ethinyl estradiol)

Recently marketed drugs

Seasonique (levonorgestrel/ethinyl estradiol)

Boniva (ibandronate)

Yaz (drosperinone/ethinyl estradiol)

Novel anticholinergic treatments

Pipeline forecasts

Contraception forecasts

Osteoporosis forecasts

Hormone replacement forecasts

Urinary incontinence forecasts

Anti-infectives forecasts

Key trends

Chapter 4 Competitive landscape

Summary

Introduction

Company market shares

Merck

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Novartis

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Bayer-Schering Pharma

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Procter & Gamble

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Wyeth

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Pfizer

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Johnson & Johnson

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Akzo Nobel/Organon

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Barr

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Watson

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Chapter 5 Appendix

IMS data

G1 Anti-infectives

G3 Hormonal contraceptives

H4 and M5 Osteoporosis

G3 Hormone replacement therapy

G2 Urinary incontinence

G2 Others

List of Figures

Figure 1.1: Typical treatment patterns in the treatment of osteoporosis

Figure 1.2: Typical treatment patterns in the treatment of urinary incontinence

Figure 2.3: Global women’s health market share by geography, 2005

Figure 2.4: Sales of types of women’s health brands, 2004-05

Figure 2.5: Competitive dynamics of the global women’s health market by drug class, 2005

Figure 2.6: Competitive dynamics of the leading 10 brands in the global women’s health market,

Figure 2.7: Competitive dynamics of subclasses of osteoporosis treatments, 2004-5

Figure 2.8: Competitive dynamics of the leading osteoporosis treatments in the global women’s

health market, 2004-5

Figure 2.9: Competitive dynamics of subclasses of hormonal contraceptives, 2004-5

Figure 2.10: Competitive dynamics of the leading hormonal contraceptive brands in the global

women’s health market, 2004-5

Figure 2.11: Competitive dynamics of subclasses of the global HRT market, 2004-5

Figure 3.12: Prevailing R&D approaches, 2006

Figure 3.13: The women’s health pipeline by indication and stage of development, 2006

Figure 3.14: Leading recently launched products and late-stage R&D compounds in the women’s

health market, 2005

Figure 4.15: Competitive dynamics of the leading players in the global women’s health market,

Figure 4.16: Merck’s women’s health sales, 2005

Figure 4.17: Novartis’ women’s health sales, 2005

Figure 4.18: Bayer-Schering Pharma’s women’s health sales, 2005

Figure 4.19: P&G’s women’s health sales, 2005

Figure 4.20: Wyeth’s women’s health sales, 2005

Figure 4.21: Pfizer’s women’s health sales, 2005

Figure 4.22: J&J’s women’s health portfolio sales, 2005

Figure 4.23: Akzo Nobel/Organon’s women’s health portfolio sales, 2005

Figure 4.24: Barr’s women’s health portfolio sales, 2005

Figure 4.25: Watson’s women’s health portfolio sales, 2005

List of Tables

Table 1.1 Estimated prevalence of women’s health conditions in the seven major pharmaceutical

markets, 2005

Table 1.2 Estimated prevalence of hip fractures use across seven major markets, 2005

Table 1.3 Forecast epidemiology of hip fractures across the seven major markets, 2005-11

Table 1.4: Estimated prevalence of hormonal contraception across seven major markets, 2005

Table 1.5: Forecast prevalent rates for epidemiology of contraceptive use across the seven major